The remarkable in vitro and in vivo anti-tumor activities of AZD5991 in both MM and AML models support its consideration as a strong clinical candidate in different Mcl-1 dependent hematologic malignancies. This evidence concerns the gene MCL1 and Miyoshi myopathy.